Skip to main content

Table 3 Toxicity

From: A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma

Hematological Toxicity Gr1 Gr2 Gr3 Gr4 Gr3 (%) Over all (%)
anemia 0 11 0 0 0 (0) 11 (26.2)
leukopenia 0 1 0 0 1 (0) 1 (2.3)
thrombocytopenia 0 2 3 0 3 (7.1) 5 (11.9)
Non-hematological Toxicity Gr1 Gr2 Gr3 Gr4 Gr3 (%) Over all (%)
nausea 3 4 1 0 1 (2.3) 8 (19.0)
vomiting 1 1 3 0 1 (2.3) 5 (11.9)
appetite loss 0 0 6 0 6 (14.3) 6 (14.3)
oral mucositis 0 4 0 0 0 (0) 4 (9.5)
taste disturbance 0 1 0 0 1 (2.3) 1 (2.3)
upper GI tract bleeding 0 1 0 0 0 (0) 1 (2.3)
diarrhea 1 0 0 0 0 (0) 1 (2.3)
general fatigue 0 1 1 0 1 (2.3) 2 (4.7)
jaundice 0 0 4 0 4 (9.5) 4 (9.5)
serum AST/ALT level elevation 0 4 1 0 1 (2.3) 1 (2.3)
Serum creatinine level elevation 0 6 0 0 0 (0) 6 (14.3)